ORCID Profile
0000-0002-7282-9227
Current Organisation
University of Technology Sydney
Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the Feedback Form.
Publisher: Elsevier BV
Date: 09-2022
Publisher: Elsevier BV
Date: 04-2017
Publisher: Oxford University Press (OUP)
Date: 11-1997
Publisher: Wiley
Date: 02-08-2018
DOI: 10.1111/BPH.14431
Publisher: MDPI AG
Date: 22-08-2023
Abstract: Cardiomyocyte loss following myocardial infarction cannot be addressed with current clinical therapies. Cell therapy with induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) is a potential approach to replace cardiomyocyte loss. However, engraftment rates in pre-clinical studies have been low, highlighting a need to refine current iPSC-CM technology. In this study, we demonstrated that inducing Yes-associated protein (YAP) by genetic and pharmacological approaches resulted in increased iPSC-CM proliferation and reduced apoptosis in response to oxidative stress. Interestingly, iPSC-CM maturation was differently affected by each strategy, with genetic activation of YAP resulting in a more immature cardiomyocyte-like phenotype not witnessed upon pharmacological YAP activation. Overall, we conclude that YAP activation in iPSC-CMs enhances cell survival and proliferative capacity. Therefore, strategies targeting YAP, or its upstream regulator the Hippo signalling pathway, could potentially be used to improve the efficacy of iPSC-CM technology for use as a future regenerative therapy in myocardial infarction.
Publisher: Elsevier BV
Date: 12-2019
Publisher: American Chemical Society (ACS)
Date: 21-08-2023
Publisher: Frontiers Media SA
Date: 30-10-2020
Location: United Kingdom of Great Britain and Northern Ireland
No related grants have been discovered for Thuy-Anh Bui.